Abstract

Biosimilars have emerged as cost-effective and clinically equivalent alternatives to reference biologics, offering significant global opportunities to improve access to essential therapies. This paper provides a conceptual review of biosimilar adoption in clinical practice, focusing on comparative effectiveness and regulatory frameworks. The analysis highlights the evidence supporting biosimilars' safety, efficacy, and immunogenicity, demonstrating their equivalence to reference products through rigorous preclinical, clinical, and real-world studies. Furthermore, the paper examines the global regulatory approaches, including those of the EMA, FDA, and WHO, highlighting their similarities, differences, and the challenges in achieving harmonization. Despite the potential benefits, barriers to widespread adoption persist, including clinician skepticism, patient concerns, and regional disparities in regulatory processes. Recommendations include enhancing regulatory efficiency, promoting education and awareness among stakeholders, strengthening pharmacovigilance systems, and implementing policies to improve access and affordability. Addressing these challenges is essential to maximize the benefits of biosimilars in achieving sustainable and equitable healthcare outcomes.